HDR Vaginal Cuff Brachytherapy Dose Recommendation
For adjuvant HDR vaginal cuff brachytherapy after hysterectomy, the standard dose schedule is 21 Gy delivered in 3 fractions of 7 Gy each, prescribed to 5 mm depth from the applicator surface, with treatments given twice weekly. 1
Dose Prescription Framework
The American Brachytherapy Society (ABS) consensus guidelines provide the most authoritative recommendations for vaginal cuff brachytherapy dosing 1. When brachytherapy is used as the sole adjuvant treatment (without external beam radiation), the following approach should be followed:
Standard Dosing Schedule
- Total dose: 21 Gy in 3 fractions of 7 Gy each
- Prescription point: 5 mm depth from applicator surface OR vaginal surface (depending on anatomy and OAR proximity)
- Treatment frequency: Twice weekly (every other day acceptable)
- Treatment duration: Typically completed within 1-2 weeks
This schedule has been validated across multiple studies with excellent local control rates (>95%) and minimal toxicity 2, 3.
Alternative Acceptable Schedule
- 20 Gy in 4 fractions of 5 Gy each is an acceptable alternative, particularly when concerned about organ-at-risk (OAR) doses 4
- This more protracted schedule may reduce acute urinary toxicity but requires additional patient visits
Critical Technical Considerations
Applicator Selection
- Use the largest diameter cylinder that fits comfortably (typically 3.5 cm preferred when anatomy permits) to ensure optimal vaginal mucosal apposition and better dose distribution 1, 5
- Smaller cylinders (2.5-3.0 cm) result in higher surface doses and potentially worse OAR dosimetry
Dose Reporting Requirements
Always report doses at BOTH locations regardless of prescription point: 1
- Vaginal surface dose
- Dose at 0.5 cm depth
This dual reporting allows for meaningful comparison between institutions and treatment techniques.
Treatment Volume
- Target the upper 3-4 cm of vaginal cuff as standard 6
- Include parametrial tissues in the clinical target volume when indicated by risk factors
Organ-at-Risk Dose Management
Dose Modification Strategy
When in vivo dosimetry or planning reveals excessive OAR doses:
- Change prescription from 5 mm depth to vaginal surface to reduce bladder and rectal doses 4
- This modification was required in 20-41% of cases in one series and significantly reduced toxicity
Dose Constraints (Based on Clinical Outcomes)
While formal constraints don't exist, clinical data suggests: 3
- Keep mean bladder dose per fraction <2.5 Gy (total <7.5 Gy) to minimize urinary toxicity 4
- D2cc to rectum typically averages 5.7 Gy (range 2.8-8.7 Gy) with acceptable toxicity
- D2cc to bladder typically averages 5.4 Gy (range 2.0-8.2 Gy) with acceptable toxicity
When Combined with External Beam Radiation
If external beam radiotherapy (EBRT) is also given (45-50 Gy), reduce brachytherapy dose accordingly 1, 7:
- Common approach: 2-3 fractions of 5-6 Gy each to vaginal surface or 5 mm depth
- Total brachytherapy dose typically 10-18 Gy when combined with EBRT
Common Pitfalls to Avoid
- Underdosing the target: Ensure adequate coverage of the entire upper vaginal cuff, not just the apex
- Inadequate applicator size: Using too small a cylinder increases surface dose and worsens dose distribution
- Delayed treatment: Initiate brachytherapy once vaginal cuff heals, but no later than 12 weeks post-surgery 8
- Ignoring OAR proximity: When rectum or bladder is close to applicator, consider surface prescription rather than 5 mm depth
- Inconsistent dose reporting: Always report both surface and 0.5 cm depth doses for quality assurance
Expected Outcomes
With the 21 Gy in 3 fractions schedule: 2, 3
- 5-year vaginal recurrence rate: <2%
- Grade 3+ toxicity: <2%
- Most toxicities are Grade 1-2 and self-limited
- Acute GI/GU toxicity: 6-10%
- Chronic GI/GU toxicity: 15%